In a two-year Phase 2 study in early AD patients carrying APOE4 alleles, ALZ-801 significantly reduced plasma p-tau181 (−31%), slowed hippocampal atrophy, and stabilized memory performance, without evidence of ARIA or vasogenic edema, supporting its disease-modifying potential [82]. This evidence concerns the gene APOE and Alzheimer disease.